![Page 1: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/1.jpg)
![Page 2: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/2.jpg)
Docetaxel Use in Prostate Cancer
Randy A. Jones, PhD, APRNAssistant Professor
University of Virginia School of Nursing
Charlottesville, Virginia
![Page 3: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/3.jpg)
What Is Docetaxel?
• The only US FDA approved chemotherapeutic agent for clinical treatment of advanced hormone refractory prostate cancer
• A chemotherapy drug that treats cancer (eg, breast, non–small-cell non–small cell lung and prostate cancer)
FDA = Food and Drug Administration.Pazdur R and Keegan P. FDA Approval for Docetaxel. Cancer Website. Available at: http://www.cancer.gov/cancertopics/druginfo/fda-docetaxel#Anchor-Prostat-16229. Accessed December 31, 2007.
![Page 4: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/4.jpg)
Drug Type of Therapy Phase Trial Overview Goals
Bevacizumab Anti-angiogenic III CALGB 90401:docetaxel/ prednisone + bevacizumab
• Eliminate/preventsymptoms
• Delay progression
Atrasentan Endothelin-1
receptor antagonist
III SWOG 04-21:docetaxel and atrasentan vs docetaxeland placebo for patients
• Delay progression• Eliminate/prevent
symptoms
Prostate GVAX Vaccine III Vital 1:GVAX® vs docetaxel + prednisone
Vital 2:docetaxel + GVAX® + prednisone vs. docetaxel + prednisone
• Delay progression
DN-101 Vitamin D receptor (Trial ended Nov 2007 for an imbalance of deaths between 2 treatment arms)
III ASCENT 2: docetaxel + prednisone + DN-101
• Effects on skeletal related events
Investigational Phase III Trials with Docetaxel
AIPC = androgen-independent prostate cancer; ASCENT = AIPC Study of Calcitriol Enhancing Taxotere; CALGB = Cancer and Leukemia Group B; DN = high-dose calcitriol; GVAX = Gene-Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines SWOG = Southwest Oncology Group.Di Lorenzo G. Drugs. 2007; 67:1109-1124; and Mendiratta P. Rev Urol. 2007;9:S9-S19 .
![Page 5: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/5.jpg)
Administration of Docetaxel
• Docetaxel is available in 20-mg (0.5 mL) or 80-mg (2 mL) vials and requires dilution prior to use
• The diluent contains 13% ethanol in water for injection
• Docetaxel is infused through the vein for approximately 1 hour every 3 weeks
![Page 6: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/6.jpg)
Dose of Docetaxel
• 75 mg/m2 IV every 3 weeks for 10 cycles• Give with 5 mg oral prednisone twice daily throughout
treatment• throughout treatment• Premedicate with dexamethasone
– Decrease or delay incidence of fluid retention and allergic reactions1
– Pretreatment regimen for hormone refractory prostate cancer is 8 mg dexamethasone at 12 hours, 3 hours,1 2 hours, and 1 hour before docetaxel infusion2
• Docetaxel + prednisone given when neutrophil count is >1500 cells/mm3
IV = intravenous.1. Piccart, M. J Clin Onc. 1997;15:3149-3155.2. Dagher R, Li N, et al. Clin Cancer Research. 2004;10:8147-8151.
![Page 7: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/7.jpg)
Docetaxel Dosage to Manage Adverse Events
Response Condition
Reduce docetaxel to 60 mg/m2 if: • Febrile neutropenia• Prolonged neutropenia• Neutropenic infection• Severe cutaneous reactions• Moderate neurosensory signs and/or
symptoms
If adverse reactions continue: • Discontinue treatment
Do not administer, or discontinue use of docetaxel if:
• Neutrophil count <1500 cells/mm3
Dagher R et al. Clin Cancer Res. 2004;10:8147-8151.
![Page 8: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/8.jpg)
Safety and Efficacy
• Treatment of metastatic prostate cancer is palliative
• Two phase 3 trials (TAX 327 and SWOG 9916) have shown improved 2 phase 3 trials (TAX 327 and SWOG 9916) have shown improved survival rate when using docetaxel– TAX 327 compared men who received Docetaxel every 3 weeks or
weekly, men who received docetaxel every 3 weeks or weekly, with men who received mitoxantrone every 3 weeks. The docetaxel every 3
weeks arm had a median survival of 18.9 months vs versus 16.5 months in the mitoxantrone arm (P = .009)
– SWOG 9916 compared docetaxel plus estramustine and mitoxantrone plus prednisone; median survival was 17.5 months for the docetaxel arm and 15.6 months among the mitoxantrone arm (P = .02). ; median survival was 17.5 months for the docetaxel arm and 15.6 months among the mitoxantrone arm (P = 0.02)
Petrylak D et al. N Engl J Med. 2004;351:1513-1520.Tannock I, et al. N Engl J Med. 2004;351:1502-1512.
![Page 9: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/9.jpg)
Maximize Benefits of Chemotherapy
• Be aware of adverse effects and anticipate treatment as needed– Minimize nausea– Adjust to hair loss– Minimize fatigue– Be aware of peripheral neuropathy – Help patient establish a support network
![Page 10: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/10.jpg)
Potential Adverse Effects of Docetaxel
• Leukopenia• Potential for fluid retention• Nausea and vomiting• Hair loss• Peripheral neuropathy• Diarrhea (drink plenty of fluids)• Fatigue (potentially from anemia)
![Page 11: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/11.jpg)
Adverse Effect: Leukopenia
• Routine blood draws are taken to identify if WBC counts are low
• Potential increased risk for infection• Monitor for fever
WBC = white blood cells
![Page 12: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/12.jpg)
Adverse Effect:Fluid Retention
• Medications
– Dexamethasone (corticosteroid) has been
seen to delay the onset of fluid retention by
decreasing potential inflammation
Piccart M. J Clin Oncol. 1997;15:3149-3155.
![Page 13: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/13.jpg)
Adverse Effect:Nausea and Vomiting
• Eat small portions of food throughout day• Eat dry foods (eg, crackers or toast)• Avoid high-fat or greasy foods• Suck on ice chips or hard candy• Medications – Dexamethasone in combination with ondansetron
![Page 14: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/14.jpg)
Adverse Effect:Hair Loss
• Usually temporary• Comb or brush hair gently• Use mild shampoo• Place sunscreen on scalp• Wear a hat when outside in the sun
![Page 15: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/15.jpg)
Adverse Effect: Peripheral Neuropathy
• Patient education includes:– Be aware of thermal injury
– Wear shoes to promote foot care
– Examine bottom of feet daily
– Report signs and symptoms of peripheral neuropathy to a healthcare provider
Visovsky C et al. Clin J Oncol Nurs. 2007;11:901-913.
![Page 16: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/16.jpg)
Adverse Effect:Fatigue
• Take scheduled rest breaks
• Join a support group
• Ask for help to accomplish activities
• Exercise– Keep muscles conditioned
– 2-site study examined resistance exercise program with a control and found men assigned to resistance exercise had less fatigue and higher quality of life than control group.* 2-site study examined resistance exercise program with a control and found men assigned to resistance exercise had less fatigue and higher quality of life than the control group
Segal R. J Clin Oncol. 2003;21:1653-1659.
![Page 17: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/17.jpg)
Help Establish Support Network
• Help patients identify trusting individuals to whom they can speak openly about their disease
• Offer a listing of surrounding support groups and resources
• Involve family members and/or friends when appropriate
![Page 18: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/18.jpg)
Other Potential Adverse Effects
• Patient may be receiving hormone therapy– May experience sexual dysfunction
• Suggest medication (eg, sildenafil, tadalafil, and vardenafil)• Suggest open discussion with sexual partner
to plan how to fulfill sexual desires
– May experience hot flashes• Recommend comfort measures—cold/warm towels (taking
in consideration for avoidance of potential thermal injury) (taking into consideration for avoidance of potential thermal injury)
• Possibly prescribe medications (ie, gabapentin)
![Page 19: Docetaxel Use in Prostate Cancer Randy A. Jones, PhD, APRN Assistant Professor University of Virginia School of Nursing Charlottesville, Virginia](https://reader036.vdocuments.site/reader036/viewer/2022082817/56649da25503460f94a8f607/html5/thumbnails/19.jpg)
Nursing Strategies to Prevent, Identify, and Manage Adverse Effects
• Assist patient to schedule uninterrupted quiet/rest times
• Provide comfort measures• Provide patient- and family-centered care• Provide education to patient and family• Be aware of patient’s concerns about
treatment/adverse effects• Develop a plan of care and evaluate its
effectiveness